Emerging Modalities

Here, we explore the next wave of therapeutics before it hits.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Emerging Modalities

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer

Emerging Modalities

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.

Emerging Modalities

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

“Cue” The Music. $7.5M for Picking the Right Molecule.

Emerging Modalities

Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.

An Oral Pill for Glioblastoma. From Oslo.

Emerging Modalities

Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.

One Patient. One B Cell. A Whole New Playbook.

Emerging Modalities

Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.

Edit the RNA. Keep the DNA. Fix the Disease.

Emerging Modalities

AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.

ADCs Hit a Wall. This Company Brought a Different Weapon.

Emerging Modalities

ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.

Your Knee Called. It Wants New Cartilage.

Emerging Modalities

Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.

No Drugs. Just Ultrasound.

Emerging Modalities

SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.

Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy

Emerging Modalities

NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.

Alltrna Sends the First tRNA Therapeutic Into Human Testing

Emerging Modalities

Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.